Roche teams with Oryzon in evolving epigenetics space
This article was originally published in Scrip
Executive Summary
Roche and Spanish firm Oryzon Genomics have teamed up to develop epigenetics-based medicines, in a deal that could see the Swiss big pharma pay out more than $500m in potential milestones.